NASDAQ$ALKS
Alkermes plc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Alkermes reported strong year-over-year growth of proprietary commercial product portfolio and announced intent to separate oncology business.
Alkermes reported Q3 2022 financial results, with total revenues of $252.4 million. Net sales of proprietary products were $199.4 million, reflecting growth in VIVITROL, ARISTADA, and LYBALVI. The company announced its intent to separate its neuroscience and oncology businesses and updated its financial expectations for full-year 2022.
- Total revenues for the quarter were $252.4 million.
- Net sales of proprietary products for the quarter were $199.4 million.
- GAAP Net loss per share was $0.39 and Non-GAAP earnings per share was $0.02
- The company announced intent to separate oncology business.
Headline financials
Revenue & EPS history
Alkermes · Revenue · Quarterly
$252M
Revenue by segment
Alkermes · $199M total across 3 segments · Q3 2022
- VIVITROL$96.5M+8.7%48.4%
- ARISTADA$75.7M+9.9%38.0%
- LYBALVI$27.1M—13.6%
Forward guidance
The company updated financial expectations for 2022, primarily reflecting LYBALVI’s launch performance to date, the company’s current assumption that it will continue to receive royalty payments related to sales of the long-acting INVEGA products outside the U.S. through the end of the year and the impact of the AMPYRA royalty revenue reversal.
Tailwinds
- Total Revenue $1,070 – $1,120 million
- VIVITROL Net Sales $370 – $380 million
- ARISTADA Net Sales $300 – $310 million
- LYBALVI Net Sales $88 – $95 million
- INVEGA Franchise Royalties $115 – $120 million
Headwinds
- Cost of Goods Sold $220 – $230 million
- R&D Expenses $385 – $400 million
- SG&A Expenses $590 – $605 million
- Amortization of Intangible Assets ~$35 million
- Interest Expense, Net $5 – $10 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-0.6%
Avg return
Earnings day
-0.0%
Avg return
5 days after
-0.5%
Avg return
30 days after
45%
27 / 60 earnings
Positive
+16.6%
Q4 2017
Best reaction
-14.8%
Q1 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.2% | +2.5% | +27.0% | |
| Q4 2025 | -6.6% | -9.4% | -12.0% | |
| Q3 2025 | +3.9% | +3.3% | +0.0% | |
| Q1 2025 | +6.3% | +5.5% | +6.4% | |
| Q4 2024 | +4.8% | +12.3% | +6.5% | |
| Q3 2024 | -6.3% | -5.1% | +3.3% | |
| Q2 2024 | +12.2% | +11.7% | +11.8% | |
| Q1 2024 | -2.8% | -1.8% | -4.6% | |
| Q4 2023 | +15.0% | +8.6% | +2.7% | |
| Q3 2023 | -2.4% | -4.0% | -3.7% | |
| Q2 2023 | -1.8% | -5.1% | -11.9% | |
| Q1 2023 | -7.1% | -6.1% | -3.9% | |
| Q4 2022 | +4.0% | +2.9% | -3.6% | |
| Q3 2022 | +3.8% | +0.3% | +12.2% | |
| Q2 2022 | -9.7% | -14.4% | -16.5% | |
| Q1 2022 | +9.8% | +6.4% | +12.5% | |
| Q4 2021 | +8.8% | +7.6% | +12.1% | |
| Q3 2021 | -8.2% | -5.0% | -28.7% | |
| Q2 2021 | +5.9% | +11.6% | +28.9% | |
| Q1 2021 | -3.2% | -1.6% | +0.8% | |
| Q4 2020 | -11.8% | -13.7% | -15.3% | |
| Q3 2020 | +5.6% | +5.9% | +20.2% | |
| Q2 2020 | -8.8% | -7.4% | -19.0% | |
| Q1 2020 | -14.8% | -14.7% | +1.6% | |
| Q4 2019 | -7.0% | -7.8% | -15.5% | |
| Q3 2019 | +5.7% | +6.0% | +13.9% | |
| Q2 2019 | -10.2% | +1.2% | -12.3% | |
| Q1 2019 | -12.2% | -12.7% | -31.1% | |
| Q4 2018 | -1.2% | +3.6% | +3.3% | |
| Q3 2018 | +3.0% | +6.5% | -11.6% | |
| Q2 2018 | -0.1% | -0.3% | +2.0% | |
| Q1 2018 | +1.5% | +1.4% | +3.9% | |
| Q4 2017 | +16.6% | +23.0% | +12.0% | |
| Q3 2017 | +0.7% | -1.5% | +3.2% | |
| Q2 2017 | -4.1% | -5.4% | -12.4% | |
| Q1 2017 | +2.0% | +2.4% | +1.0% | |
| Q4 2016 | -2.9% | -4.6% | +3.7% | |
| Q3 2016 | -1.4% | +4.0% | +8.4% | |
| Q2 2016 | -3.6% | -6.0% | -14.1% | |
| Q1 2016 | -2.0% | — | — | |
| Q4 2015 | -1.4% | — | — | |
| Q3 2015 | +7.6% | — | — | |
| Q2 2015 | +2.4% | — | — | |
| Q1 2015 | +3.1% | — | — | |
| Q4 2014 | -3.4% | — | — | |
| Q3 2014 | +7.7% | — | — | |
| Q2 2014 | -7.2% | — | — | |
| Q1 2014 | +3.2% | — | — | |
| Q4 2013 | -7.7% | — | — | |
| Q3 2013 | -3.7% | — | — | |
| Q2 2013 | +3.5% | — | — | |
| Q1 2013 | +3.9% | — | — | |
| Q4 2010 | -1.0% | — | — | |
| Q4 2012 | -9.9% | — | — | |
| Q3 2012 | +2.2% | — | — | |
| Q3 2011 | +2.2% | — | — | |
| Q2 2011 | -7.7% | — | — | |
| Q2 2012 | -7.7% | — | — | |
| Q4 2011 | -7.7% | — | — | |
| Q2 2010 | -3.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro